EULAR Recommendations for the Management and Vaccination of People with Rheumatic and Musculoskeletal Diseases in the Context of SARS-CoV-2: The November 2021 Update
Robert B M Landewé
(1)
,
Féline P B Kroon
,
Alessia Alunno
(2)
,
Aurélie Najm
(3)
,
Johannes Wj Bijlsma
(4)
,
Gerd-Rüdiger R Burmester
,
Roberto Caporali
(5)
,
Bernard Combe
(6)
,
Richard Conway
,
Jeffrey R Curtis
,
Ori Elkayam
(7)
,
Laure Gossec
(8, 9)
,
Marloes W Heijstek
,
Lukas Haupt
,
Annamaria Iagnocco
(10)
,
John D Isaacs
,
István Ábel Juhász
,
Suzi Makri
,
Xavier Mariette
(11)
,
Iain B Mcinnes
,
Puja Mehta
(12, 13)
,
Ulf Mueller-Ladner
,
Hendrik Schulze-Koops
(14)
,
Josef S Smolen
,
Dieter Wiek
,
Kevin L Winthrop
,
Victoria Navarro-Compán
(15)
,
Pedro M Machado
1
AMC -
Academic Medical Center - Academisch Medisch Centrum [Amsterdam]
2 UNIVAQ - University of L'Aquila [Italy]
3 University of Glasgow
4 University Medical Center [Utrecht]
5 UNIMI - Università degli Studi di Milano = University of Milan
6 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
7 Tel Aviv Sourasky Medical Center [Te Aviv]
8 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique
9 CHU Pitié-Salpêtrière [AP-HP]
10 UNITO - Università degli studi di Torino = University of Turin
11 Hôpital Bicêtre
12 UCL - University College of London [London]
13 NHS Foundation Trust [London]
14 LMU - Ludwig Maximilian University [Munich] = Ludwig Maximilians Universität München
15 Hospital Universitario La Paz
2 UNIVAQ - University of L'Aquila [Italy]
3 University of Glasgow
4 University Medical Center [Utrecht]
5 UNIMI - Università degli Studi di Milano = University of Milan
6 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
7 Tel Aviv Sourasky Medical Center [Te Aviv]
8 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique
9 CHU Pitié-Salpêtrière [AP-HP]
10 UNITO - Università degli studi di Torino = University of Turin
11 Hôpital Bicêtre
12 UCL - University College of London [London]
13 NHS Foundation Trust [London]
14 LMU - Ludwig Maximilian University [Munich] = Ludwig Maximilians Universität München
15 Hospital Universitario La Paz
Féline P B Kroon
- Function : Author
Gerd-Rüdiger R Burmester
- Function : Author
Richard Conway
- Function : Author
Jeffrey R Curtis
- Function : Author
Marloes W Heijstek
- Function : Author
Lukas Haupt
- Function : Author
John D Isaacs
- Function : Author
István Ábel Juhász
- Function : Author
Suzi Makri
- Function : Author
Iain B Mcinnes
- Function : Author
Ulf Mueller-Ladner
- Function : Author
Josef S Smolen
- Function : Author
Dieter Wiek
- Function : Author
Kevin L Winthrop
- Function : Author
Pedro M Machado
- Function : Author
Abstract
The first EULAR provisional recommendations on the management of rheumatic and musculoskeletal diseases (RMDs) in the context of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), largely based on expert opinion, were published in June 2020. Since then, an unprecedented number of clinical studies have accrued in the literature. Several SARS-CoV-2 vaccines have been approved for population-wide vaccination programmes in EULAR-affiliated countries. Studies regarding vaccination of patients with (inflammatory) RMDs have released their first results or are underway. EULAR found it opportune to carefully review to what extent the initially consensus expert recommendations stood the test of time, by challenging them with the recently accumulated body of scientific evidence, and by incorporating evidence-based advice on SARS-CoV-2 vaccination. EULAR started a formal (first) update in January 2021, performed a systematic literature review according to EULAR's standard operating procedures and completed a set of updated overarching principles and recommendations in July 2021. Two points to consider were added in November 2021, because of recent developments pertaining to additional vaccination doses.